Share Making The Cut Podcast
Share to email
Share to Facebook
Share to X
Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With their unique Engineering Biology platforms, Sherlock Biosciences is on the cusp of solving challenges ranging from faster pathogen detection, cancer detection, and improved food safety.
Brian discusses Lineage's exclusive worldwide collaboration and license agreement with Roche and Genentech for the development and commercialization of OpRegen- a retinal pigment epithelium cell therapy.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering to industrialize drug discovery.
Hyperfine was founded with a vision to save lives by making Magnetic Resonance Imaging (MRI) more accessible and affordable.
Beam Therapeutics is pioneering the use of base editing, a new class of precision genetic medicines with a vision of providing life-long cures to patients suffering from serious diseases.
Mammoth Biosciences is a San Francisco based biotechnology company developing diagnostic tests using CRISPR-Cas12 and ultra-small CRISPR nucleases.
The podcast currently has 7 episodes available.